Panacea Biotech Receives Update to UNICEF Contract for Easyfive Vaccine
Panacea Biotech has received an update to its UNICEF contract for supplying the WHO pre-qualified pentavalent vaccine, Easyfive-TT (DTwP-HepB-Hib), for 2023-2027. The contract value for 2026 has increased by $2.55 million (about ₹23 crore) to $16.8 million. For 2027, it has risen by $2.70 million (around ₹24 crore) to $15.18 million. Additionally, the company got a new award for 2027 worth $3.68 million (≈₹33 crore).
This update is a significant development for Panacea Biotech, as it reinforces the company’s position as a leading vaccine manufacturer in India. The increased order value is also expected to have a positive impact on the company’s revenue and profitability in the coming years.
Impact on Indian Pharmaceutical Sector
The increased order value for Easyfive vaccine is also a testament to the growing demand for vaccines in the global market. As a leading vaccine manufacturer in India, Panacea Biotech is well-positioned to capitalize on this trend. The company’s expertise in vaccine manufacturing and its strong relationships with international organizations such as UNICEF have enabled it to secure large orders and expand its presence in the global market.
For Indian investors and traders, this development is a positive sign for the pharmaceutical sector as a whole. The sector has been experiencing significant growth in recent years, driven by increasing demand for healthcare services and products. As the demand for vaccines and other pharmaceutical products continues to rise, companies like Panacea Biotech are likely to benefit from this trend. To learn more about the pharmaceutical sector in India, readers can visit our website.
Shares of Panacea Biotech Rise on NSE
The shares of Panacea Biotech closed at ₹359.50, up 0.93% on the NSE today, December 24. This increase in stock price is a reflection of the positive sentiment among investors and traders, who are expecting the company to benefit from the increased order value for Easyfive vaccine.
For investors who are looking to invest in the pharmaceutical sector, this development is a positive sign. The sector is expected to continue growing in the coming years, driven by increasing demand for healthcare services and products. To learn more about investing in the pharmaceutical sector, readers can visit our website.
Earlier Order for Polio Vaccines
Earlier in October, UNICEF also placed a significant order for polio vaccines. Panacea Biotec received the letter of award (LoA) as part of a long-term agreement to supply bOPV in 10 and 20-vial presentations to the UN agency from April 1, 2026, to March 31, 2030.
This order is a testament to the company’s expertise in vaccine manufacturing and its strong relationships with international organizations such as UNICEF. The company’s ability to secure large orders and expand its presence in the global market is a positive sign for its future growth and profitability.
Conclusion
In conclusion, the update to Panacea Biotech’s UNICEF contract for Easyfive vaccine is a significant development for the company and the Indian pharmaceutical sector as a whole. The increased order value is expected to have a positive impact on the company’s revenue and profitability in the coming years, and is a testament to the growing demand for vaccines in the global market. For Indian investors and traders, this development is a positive sign for the pharmaceutical sector, and is expected to drive growth and profitability in the coming years. To learn more about Indian stock market trends, readers can visit our website.